ATARA Biotherapeutics (ATRA) Prices 12.63M Share Common Offering at $11.32/Sh

After-Hours Stock Movers 05/26: (CPIX) (HTZ) (STNE) Higher; (VSAT) (KEYS) (IIPR) Lower (more...)

Today's After-Hours Stock Movers:

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) 37% HIGHER; announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis. Vibativ® (telavancin) is a potent, FDA-approved anti-infective for the treatment of serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia. It is also approved for complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

Hertz Global Holdings,... More

ATARA Biotherapeutics (ATRA) Announces Proposed Common Share & Pre-Funded Warrants Offering

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) today announced that it has commenced an underwritten public offering of shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of its common stock. The pre-funded warrants will be offered at the same price per share as the common... More

ATARA Biotherapeutics (ATRA) Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive MS in Late-Breaking e-Poster at EAN

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of additional safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive... More